Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer.
Hillner
B E
BE
Roberts
J D
JD
D000726:Androgen Antagonists / Q000191:economics*; D018931:Antineoplastic Agents, Hormonal / Q000191:economics*; D002755:Choice Behavior; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D016527:Drug Costs / Q000706:statistics & numerical data; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D017721:Hospital Costs / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D006278:Medicare; D009919:Orchiectomy / Q000191:economics*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D017430:Prostate-Specific Antigen